Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [68Ge]Ge/[68Ga]Ga Generators: Fractional Elution or Prepurification?
- PMID: 38004410
- PMCID: PMC10674510
- DOI: 10.3390/ph16111544
Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [68Ge]Ge/[68Ga]Ga Generators: Fractional Elution or Prepurification?
Abstract
Prostate cancer is one of the most common forms of cancer in men. An imaging technique for its diagnosis is [68Ga]-prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) positron emission tomography (PET). To address the increasing demand for [68Ga]-labeled peptides and reduce the cost of radiosynthesis, it is therefore necessary to optimize the elution process of [68Ge]Ge/[68Ga]Ga generators. This study aims to identify the most effective approach for optimizing radiosynthesis using double elution in parallel of two [68Ge]Ge/[68Ga]Ga generators. Two methods have been tested: one using prepurification, and the other using fractionated elution. Five synthesis sequences were conducted using each method. The mean labeling yields for double elution with prepurification were 45.8 ± 29.4 (mean ± standard deviation) and none met the required criteria. The mean labeling yields for the fractionated double elution were 97.5 ± 1.9 (mean ± standard deviation) meeting the criteria, significantly superior to the prepurification method (p = 0.012), and similar to those of simple elution. This study showed that fractionated double elution from [68Ge]Ge/[68Ga]Ga generators produced a significantly higher labeling yield than double elution with prepurification, resulting in a larger activity recovered via radiosynthesis, thereby allowing more diagnostic tests to be performed.
Keywords: [68Ga]Ga-PSMA-11; double elution; radiopharmacy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Dyba T., Randi G., Bray F., Martos C., Giusti F., Nicholson N., Gavin A., Flego M., Neamtiu L., Dimitrova N., et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur. J. Cancer. 1990;157:308–347. doi: 10.1016/j.ejca.2021.07.039. - DOI - PMC - PubMed
-
- Protocole D’utilisation Thérapeutique et de Recueil D’informations PSMA-11 10 µg, Poudre Pour Solution Injectable. Janvier 2022. [(accessed on 1 April 2023)]. Available online: https://ansm.sante.fr/uploads/2022/01/10/20220110-aac-psma-11-put-01-22.pdf.
-
- Perera M., Papa N., Roberts M., Williams M., Udovicich C., Vela I., Christidis D., Bolton D., Hofman M.S., Lawrentschuk N., et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur. Urol. 2020;77:403–417. - PubMed
LinkOut - more resources
Full Text Sources